Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
I had considered that as the most realistic option, just wondered if there was a way to use unknowns. Thanks for your input.
-
DESeq2 unknown treatment option?
Hi all,
I am wondering how I can include 'unknown' treatment/condition of samples in my design. I have two factors, one is method of mRNA preparation (RiboZero or PolyA), the second is 'responder' or 'non-responder' to a drug that has been administered. There is some missing data here, so about 1/4 of samples are classified 'undetermined response'. At first I thought to include a simple 'unknown' condition, but samples are either responsive to treatment or not. Therefore I thought that classifying a third condition in this way would not make sense. Is there a way to include no information for those samples not designated 'responder'/'non-responder'?
Thanks, Bruce.Tags: None
Latest Articles
Collapse
-
by seqadmin
The complexity of cancer is clearly demonstrated in the diverse ecosystem of the tumor microenvironment (TME). The TME is made up of numerous cell types and its development begins with the changes that happen during oncogenesis. “Genomic mutations, copy number changes, epigenetic alterations, and alternative gene expression occur to varying degrees within the affected tumor cells,” explained Andrea O’Hara, Ph.D., Strategic Technical Specialist at Azenta. “As...-
Channel: Articles
07-08-2024, 03:19 PM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, 07-25-2024, 06:46 AM
|
0 responses
9 views
0 likes
|
Last Post
by seqadmin
07-25-2024, 06:46 AM
|
||
Started by seqadmin, 07-24-2024, 11:09 AM
|
0 responses
26 views
0 likes
|
Last Post
by seqadmin
07-24-2024, 11:09 AM
|
||
Started by seqadmin, 07-19-2024, 07:20 AM
|
0 responses
160 views
0 likes
|
Last Post
by seqadmin
07-19-2024, 07:20 AM
|
||
Started by seqadmin, 07-16-2024, 05:49 AM
|
0 responses
127 views
0 likes
|
Last Post
by seqadmin
07-16-2024, 05:49 AM
|
Leave a comment: